1. FDA‐NIH:Biomarker‐Working‐Group (2016) BEST (Biomarkers, EndpointS, and other Tools) Resource. Maryland: Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US), 2016.
2. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews;Struewing;N. Engl. J. Med.,1997
3. Population-based study of risk of breast cancer in carriers of BRCA2 mutation;Thorlacius;Lancet,1998
4. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue;Scott;Blood,2014
5. J.I. Epstein, L. Egevad, M.B. Amin, B. Delahunt, J.R. Srigley, P.A. Humphrey, The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System, Am. J. Surg. Pathol., 40 (2016) 244-252.